Osteoporotic bone fracture risk assessment in Latvian patients with newly diagnosed sarcoidosis
Main Article Content
Keywords
osteoporosis, sarcoidosis, vitamin D, calcium, bone, bone fracture risk, fracture risk assessment, fractures, hypercalcaemia, hypercalciuria
Abstract
Background and aim: Increased calcitriol synthesis in sarcoid granulomas with subsequent hypercalcaemia and hypercalciuria can affect bone metabolism in patients with sarcoidosis. Multiple factors can increase the fracture risk in patients with sarcoidosis. This study aimed to evaluate a 10-year osteoporotic and a 10-year hip fracture risk and to analyse factors affecting fracture risk for patients with newly diagnosed sarcoidosis compared to an age- and gender-matched control group from a real-world setting. Methods: The cross-sectional study included 171 patients with a histologically verified diagnosis of sarcoidosis who were hospitalised due to suspected sarcoidosis within two years and an age- and gender-matched control group of 178 hospitalised individuals. QFracture algorithm questions were asked during interviews. Results: A cohort of 349 subjects was analysed. The median age in the patient group was 40 years (IQR:20), and 60.2% were female. 21.6% of patients with sarcoidosis had at least one comorbidity that could potentially influence the osteoporotic fracture risk. Both the median 10-year osteoporotic fracture risk (0.9% (IQR:2) vs 1.3% (IQR:2.3), p=0.005; U=12394) and a 10-year hip fracture risk (0.1% (IQR:0.3) vs 0.2% (IQR:0.5), p=0.003; U=12368.5) was lower in patients with sarcoidosis compared to control group subjects. As compared to the control group, individuals with sarcoidosis exhibited a lower frequency of both osteoporotic (2.4% vs 11.2%, OR=0.189 (95% CI:0.063-0.566), p=0.003) and low-energy trauma fractures (2.9% vs 11.8%, OR=0.225 (95% CI:0.083-0.612), p=0.003) in personal medical history. Conclusions: This was the first study to investigate osteoporotic fracture risk and related factors in Latvian patients with newly diagnosed sarcoidosis. Our data show a lower risk of a 10-year osteoporotic and a 10-year hip fracture risk in patients with sarcoidosis compared to age- and gender-matched control group subjects from a real-world setting.
References
2. Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary sarcoidosis. Lancet Respir Med. 2018 May;6(5):389-402. doi:10.1016/S2213-2600(18)30064-X.
3. Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med. 2020 Sep 30;21(3):321-338. doi:10.31083/j.rcm.2020.03.102.
4. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-755. doi:10.1164/ajrccm.
5. Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020 Sep;26(5):527-534. doi:10.1097/MCP.0000000000000715.
6. Ruza I, Plegermane A. Serum and urinary calcium level in Latvian patients with sarcoidosis at the time of diagnosis–2013–2018 data. Endocrine Abstracts (2021) 73 AEP133 doi:10.1530/endoabs.73.AEP133.
7. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. doi:10.1513/AnnalsATS.201511-760OC.
8. Hena KM. Sarcoidosis Epidemiology: Race Matters. Front Immunol. 2020 Sep 15;11:537382. doi:10.3389/fimmu.2020.537382.
9. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014 Mar 29;383(9923):1155-1167. doi:10.1016/S0140-6736(13)60680-7.
10. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016 Oct;37(5):521-547. doi:10.1210/er.2016-1070.
11. Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010 Apr;104(4):564-570. doi:10.1016/j.rmed.2009.12.004.
12. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health issues in sarcoidosis. Curr Rheumatol Rep. 2011 Jun;13(3):265-272. doi:10.1007/s11926-011-0170-1.
13. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford). 2000 Jul;39(7):707-713. doi:10.1093/rheumatology/39.7.707.
14. Ruža I, Lucāne Z. Serum and urinary calcium level in Latvian patients with sarcoidosis. Reumatologia. 2018;56(6):377-381. doi:10.5114/reum.2018.80715.
15. Cameli P, Gonnelli S, Bargagli E, et al. The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients. Respiration. 2020;99(3):207-212. doi:10.1159/000505653.
16. Calatroni M, Moroni G, Reggiani F, Ponticelli C. Renal sarcoidosis. J Nephrol. 2023 Jan;36(1):5-15. doi:10.1007/s40620-022-01369-y.
17. Saidenberg-Kermanac'h N, Semerano L, Nunes H, et al. Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients. Arthritis Res Ther. 2014 Mar 24;16(2):R78. doi:10.1186/ar4519.
18. Caffarelli C, Cameli P, Al Refaie A et al.. Bone fragility and sarcoidosis: An underestimated relationship. Front Med (Lausanne). 2022;9:1026028. doi:10.3389/fmed.2022.1026028
19. Zhou Y, Lower EE. Balancing Altered Calcium Metabolism with Bone Health in Sarcoidosis. Semin Respir Crit Care Med. 2020 Oct;41(5):618-625. doi:10.1055/s-0040-1713009.
20. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi:10.1002/art.40137.
21. Baughman RP, Lower EE. Goldilocks, vitamin D and sarcoidosis. Arthritis Res Ther. 2014;16(3):111. doi:10.1186/ar4568.
22. Oshagbemi OA, Driessen JHM, Pieffers A, et al. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis. Osteoporos Int. 2017 Oct;28(10):2859-2866. DOI:10.1007/s00198-017-4115-z.
23. Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe. J Bone Miner Res. 2014 Nov;29(11):2498-2503. doi:10.1002/jbmr.2262.
24. Bolland MJ, Wilsher ML, Grey A, et al. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013 Oct 23;3(10):e003562. doi:10.1136/bmjopen-2013-003562.
25. Yong WC, Upala S, Sanguankeo A. Bone Mineral Loss and Fracture in Sarcoidosis: A Systematic Review and Meta-Analysis. Arch Rheumatol. 2019 Jun;34(2):130-140. doi:10.5606/ArchRheumatol.2019.6883.
26. Brismar TB, Shams S, Berinder K, et al. Glucocorticoids and Sarcoidosis: A Longitudinal Study on the Effects on Cortical and Trabecular Bone. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22;32(1):63-69.
27. Alhamad EH, Nadama R. Bone mineral density in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jul 22;32(2):151-9.
28. Wysham KD, Baker JF, Shoback DM. Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol. 2021 May 1;33(3):270-276. doi:10.1097/BOR.0000000000000789.
29. Zhao X, Zhou C, Chen H, et al. Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Medicine (Baltimore). 2017 Mar;96(11):e6378. doi:10.1097/MD.0000000000006378.
30. Heijckmann AC, Huijberts MS, De Vries J, et al. Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007 Mar;24(1):51-58.
31. Heijckmann AC, Drent M, Dumitrescu B, et al. Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int. 2008 Jun;19(6):839-847. doi:10.1007/s00198-007-0513-y.
32. Ungprasert P, Crowson CS, Matteson EL. Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013-supplementary presentation. Osteoporos Int. 2018 May;29(5):1201. doi:10.1007/s00198-017-4074-4.
33. Bours S, de Vries F, van den Bergh JPW, et al. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort. Osteoporos Int. 2016 Apr;27(4):1603-1610. doi:10.1007/s00198-015-3426-1
34. Ungprasert P, Matteson EL, Crowson CS. Increased Risk of Multimorbidity in Patients With Sarcoidosis: A Population-Based Cohort Study 1976 to 2013. Mayo Clin Proc. 2017 Dec;92(12):1791-1799. doi:10.1016/j.mayocp.2017.09.015.
35. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012 May 22;344:e3427. doi:10.1136/bmj.e342.
36. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ. 2011 Jun 22;342:d3651. doi:10.1136/bmj.d3651.
37. Lejnieks A, Slaidina A, Zvaigzne A, et al. Vitamin D Status and Its Seasonal Variations and Association With Parathyroid Hormone Concentration in Healthy Women in Riga. Medicina [Internet]. MDPI AG; 2013 Jun 22;49(7):51. doi:10.3390/medicina49070051.
38. Gregson CL. CFracture, an alternative to QFracture that accounts for mortality to better predict fragility fracture risk. Lancet Healthy Longev. 2023 Jan;4(1):e6-e7. doi:10.1016/S2666-7568(22)00293-8.
39. Livingstone SJ, Guthrie B, McMinn M, et al. Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. Lancet Healthy Longev. 2023 Jan;4(1):e43-e53. doi:10.1016/S2666-7568(22)00290-2.
40. Livingstone SJ, Morales DR, McMinn M, et al. Effect of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population. BMJ Med. 2022 Oct 25;1(1):e000316. doi:10.1136/bmjmed-2022-000316. Erratum in: BMJ Med. 2023 Jul 10;2(1):e000316corr1.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Ieva Ruza, Department of Endocrinology, Riga East Clinical University Hospital, Riga, Latvia
Department of Endocrinology, Riga East Clinical University Hospital, Riga, Latvia
Zane Lucane, Department of Internal Medicine, Riga Stradins University, Riga, Latvia
Department of Internal Medicine, Riga Stradins University, Riga, Latvia
Elina Vanaga, Department of Internal Medicine, Riga Stradins University, Riga, Latvia
Department of Endocrinology, Riga East Clinical University Hospital, Riga, Latvia
Marta Persana, Department of Internal Medicine, Riga Stradins University, Riga, Latvia
Department of Internal Medicine, Riga Stradins University, Riga, Latvia
Zane Vitenberga-Verza, Department of Pathology, Riga East Clinical University Hospital, Riga, Latvia
Department of Pathology, Riga East Clinical University Hospital, Riga, Latvia
Ilze Strumfa, Department of Pathology, Riga Stradins University, Riga, Latvia
Department of Pathology, Riga Stradins University, Riga, Latvia
How to Cite
